Research Paper Volume 13, Issue 24 pp 26180—26200

NAP1L1 promotes proliferation and chemoresistance in glioma by inducing CCND1/CDK4/CDK6 expression through its interaction with HDGF and activation of c-Jun


Figure 1. NAP1L1 is highly expressed in glioma and correlates with poor prognosis. (A) NAP1L1 mRNA expression in glioma tissues and para-tumor tissues among the glioma patients obtained from the TCGA database. (B) Kaplan-Meier survival analysis for overall survival based on the NAP1L1 expression data. (C) RT-qPCR analysis of NAP1L1 mRNA expression in 24 glioma tissues and 24 para-tumor tissues. (D, E) Representative images of NAP1L1 staining (D) and IHC score (E) of in (grade I–IV) glioma tissues (scale bar: 50 μm). (F, G) Kaplan-Meier survival analysis for overall survival (F) and Disease Free survival (G) in TMA showing NAP1L1 expression. Data are presented as the mean ± SD for three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.